If, as anticipated, ABI’s new study demonstrates the efficacy and safety of this treatment regimen, ABI intends to conduct a Phase III study before filing a marketing approval application for interferon alpha lozenges in the treatment of oral warts in HIV-positive patients.
In a related development, ABI announced that it has retained The Patient Recruiting Agency (TPRA) of Austin, Texas to accelerate enrollment in its Phase II clinical trial of oral warts in HIV positive patients. TPRA will design a multi-media campaign that will include print, television and Internet advertising, plus a grassroots awareness effort.